{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:20:55Z","timestamp":1787944855908,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Currently available treatments have only been partly successful in patients with severe hypertriglyceridemia, including those with high serum triglycerides above 1,000\u00a0mg\/dL (11.3\u00a0mmol\/L), who often suffer from acute pancreatitis. Pemafibrate is a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1) which has been developed as an affordable oral tablet in Japan. We herein report the first three patients with severe hypertriglyceridemia who were successfully treated with pemafibrate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Three patients with fasting serum triglyceride (TG) levels above 1,000\u00a0mg\/dL (11.3\u00a0mmol\/L) were treated with pemafibrate (0.2\u20130.4\u00a0mg\/day, 0.1\u20130.2\u00a0mg BID).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Serum TGs decreased from 2,000\u20133,000\u00a0mg\/dL (22.6\u201333.9\u00a0mmol\/L) to\u2009&lt;\u2009250\u00a0mg\/dL (2.8\u00a0mmol\/L) without adverse effects in all three patients. Serum TGs in Patient 1 and 2 decreased from 1,326\u00a0mg\/dL (15.0\u00a0mmol\/L) to 164\u00a0mg\/dL (1.9\u00a0mmol\/L) and from 2,040\u00a0mg\/dL (23.1\u00a0mmol\/L) to 234\u00a0mg\/dL (2.6\u00a0mmol\/L), respectively. Patient 3 with type 2 diabetes and 12.1% (109\u00a0mmol\/mol) hemoglobin A1c had a TG level of 2,300\u00a0mg\/dL (26.0\u00a0mmol\/L). Even after glycemic control improved, TG remained high. After pemafibrate administration, TG decreased to 200\u00a0mg\/dL (2.3\u00a0mmol\/L). All patients showed no serious adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pemafibrate demonstrated potential efficacy and safety for severe hypertriglyceridemia which may contribute to the prevention of acute pancreatitis, in a manner that can be easily prescribed and used as an oral tablet.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12933-020-01172-8","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T11:03:08Z","timestamp":1606474988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Marked effects of novel selective peroxisome proliferator-activated receptor \u03b1 modulator, pemafibrate in severe hypertriglyceridemia: preliminary report"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5459-4252","authenticated-orcid":false,"given":"Chie","family":"Iitake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Koseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"1172_CR1","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","volume":"375","author":"M Jun","year":"2010","unstructured":"Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875\u201384.","journal-title":"Lancet"},{"key":"1172_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/1476-511X-10-157","volume":"10","author":"S Sandhu","year":"2011","unstructured":"Sandhu S, Al-Sarraf A, Taraboanta C, Frohlich J, Francis GA. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis. 2011;10:157.","journal-title":"Lipids Health Dis"},{"key":"1172_CR3","first-page":"756","volume":"8","author":"MF James","year":"2018","unstructured":"James MF. Familial chylomicronemia syndrome: a clinical guide for endocrinologists. Endocr Pract. 2018;8:756\u201363.","journal-title":"Endocr Pract"},{"key":"1172_CR4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/FPC.0b013e328340095e","volume":"20","author":"D Brisson","year":"2010","unstructured":"Brisson D, M\u00e9thot J, Tremblay K, Tremblay M, Perron P, Gaudet D. Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics. Pharmacogenet Genomics. 2010;20:742\u20137.","journal-title":"Pharmacogenet Genomics"},{"key":"1172_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12933-019-0864-7","volume":"18","author":"JC Fruchart","year":"2019","unstructured":"Fruchart JC, Santos RD, Aguilar-Salinas C, et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM\u03b1) paradigm: conceptual framework and therapeutic potential: a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc Diabetol. 2019;18:71.","journal-title":"Cardiovasc Diabetol"},{"key":"1172_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"S Ishibashi","year":"2018","unstructured":"Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018;12:173\u201384.","journal-title":"J Clin Lipidol"},{"key":"1172_CR7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.14740\/jocmr3949","volume":"11","author":"C Iitake","year":"2019","unstructured":"Iitake C, Iitake K. Half dose once-daily pemafibrate effectively improved hypertriglyceridemia in real practice. J Clin Med Res. 2019;11:690\u20135.","journal-title":"J Clin Med Res"},{"key":"1172_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1258\/acb.2012.011163","volume":"49","author":"V Ncube","year":"2012","unstructured":"Ncube V, Starkey B, Wang T. Effect of fenofibrate treatment for hyperlipidaemia on serum creatinine and cystatin C. Ann Clin Biochem. 2012;49:491\u20133.","journal-title":"Ann Clin Biochem"},{"key":"1172_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/17425255.2018.1483337","volume":"14","author":"MS Hedrington","year":"2018","unstructured":"Hedrington MS, Davis SN. Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver. Expert Opin Drug Metab Toxicol. 2018;14:671\u20137.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1172_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1499-3872(14)60033-3","volume":"13","author":"G Sisman","year":"2014","unstructured":"Sisman G, Erzin Y, Hatemi I, et al. Familial chylomicronemia syndrome related chronic pancreatitis: a single-center study. Hepatobiliary Pancreat Dis Int. 2014;13:209\u201314.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"1172_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","volume":"206","author":"AD Pradhan","year":"2018","unstructured":"Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart J. 2018;206:80\u201393.","journal-title":"Am Heart J"},{"key":"1172_CR12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.5551\/jat.GL2017","volume":"25","author":"M Kinoshita","year":"2018","unstructured":"Kinoshita M, Yokote K, Arai H, et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb. 2018;25:846\u2013984.","journal-title":"J Atheroscler Thromb"},{"key":"1172_CR13","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1194\/jlr.P800011-JLR200","volume":"49","author":"CR Pullinger","year":"2008","unstructured":"Pullinger CR, Aouizerat BE, Movsesyan I, et al. An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients. J Lipid Res. 2008;49:1846\u201354.","journal-title":"J Lipid Res"},{"key":"1172_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/MOL.0b013e3283555a7e","volume":"23","author":"D Gaudet","year":"2012","unstructured":"Gaudet D, M\u00e9thot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol. 2012;23:310\u201320.","journal-title":"Curr Opin Lipidol"},{"key":"1172_CR15","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371:2200\u20136.","journal-title":"N Engl J Med"},{"key":"1172_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531\u201342.","journal-title":"N Engl J Med"},{"key":"1172_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377:211\u201321.","journal-title":"N Engl J Med"},{"key":"1172_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","volume":"377","author":"MJ Graham","year":"2017","unstructured":"Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377:222\u201332.","journal-title":"N Engl J Med"},{"key":"1172_CR19","unstructured":"Arrowhead Pharmaceuticals. Pipeline: Novel drugs to treat intractable diseases (https:\/\/arrowheadpharma.com\/pipeline\/) (Accessed on 29 October, 2020)."},{"key":"1172_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.5551\/jat.39693","volume":"25","author":"M Sairyo","year":"2018","unstructured":"Sairyo M, Kobayashi T, Masuda D, et al. A novel selective PPAR\u03b1 modulator (SPPARM\u03b1), K-877 (pemafibrate), attenuates postprandial hypertriglyceridemia in mice. J Atheroscler Thromb. 2018;25:142\u201352.","journal-title":"J Atheroscler Thromb"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01172-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-020-01172-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01172-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T15:57:00Z","timestamp":1618502220000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01172-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01172-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"assertion":[{"value":"19 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Each patient was given enough information about the aim and concept of the study and agreed to provide their laboratory data in an unidentified form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.Y reports a lecture fee and M.K. reports a grant from Kowa Co. during the conduct of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}